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ABSTRACT
IMPACT OF PANK1 DELETION ON MITOCHONDRIAL
ACETYLATION AND CARDIAC FUNCTION DURING
PRESSURE OVERLOAD
Timothy N. Audam
August 6th, 2021

Recent studies have associated elevated protein acetylation levels with heart failure in
humans. Although mechanisms promoting elevated acetylation levels are not fully known,
excess acetyl-CoA may drive enzyme-independent acetylation of cardiac proteins.
Accumulation of acetyl-CoA depends on the availability of sufficient CoA, whose
production is regulated by pantothenate kinases in the CoA biosynthetic pathway. We
show that cardiac proteins are hyperacetylated during heart failure in humans and tested
in mice whether limiting CoA abundance would improve ventricular remodeling during
pressure overload-induced hypertrophy. We limited cardiac CoA levels by deleting the
rate-limiting enzyme in CoA biosynthesis, Pank1 (one of three PANK-encoding genes in
mice). We reasoned that this strategy would at least partially limit the driving force (excess
acetyl-CoA) for acetylation in the failing heart. We found that constitutive, cardiomyocytespecific Pank1 deletion (cmPank1-/-) significantly reduced PANK1 mRNA, PANK1 protein,
and CoA levels compared to Pank1 sufficient littermates (cmPank1+/+) but exerted no
obvious deleterious impact on the mice. We then subjected both groups of mice to
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pressure overload-induced heart failure. Interestingly, despite limiting acetyl-CoA and
acetylation levels in cmPank1-/- mice, there was more ventricular dilation in cmPank1-/during pressure overload. To explore potential mechanisms contributing to this
unanticipated result, we performed transcriptomic profiling, which suggested a role for
Pank1 in regulating fibrotic and metabolic processes during pressure overload. Indeed,
Pank1 deletion exacerbated cardiac fibrosis following pressure overload. Because we
were interested in the possibility of early metabolic impacts in response to pressure
overload, we performed untargeted metabolomics, which indicated significant changes to
metabolites involved in fatty acid and ketone metabolism, among other pathways.

Lastly, coincident with increased acetylation observed during heart failure, mitochondrial
respirasomes (supercomplexes) composition was changed during heart failure and may
contribute to reduced mitochondria efficiency; however, it is not known whether acetylation
directly affects mitochondrial respirasomes. We showed that reducing mitochondria
acetylation alone does not impact mitochondria respirasomes, mitochondria function, or
mitochondria dynamics. Furthermore, we did not observe any significant impact in
mitochondrial supercomplexes when mitochondria hyperacetylation was induced.

Briefly, our study underscores the role of elevated CoA levels (via Pank1) in supporting
fatty acid and ketone body oxidation, which may be more important than CoA-driven,
enzyme-independent acetylation in the failing heart. We also showed that changing
mitochondrial acetylation alone does not impact mitochondria supercomplexes.
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CHAPTER I
BACKGROUND AND LITERATURE REVIEW
According to the Center for Disease Control and Prevention (CDC), cardiovascular
diseases (CVD) remain the leading cause of death across most demographics in the
United States. In the United States, one person dies every 36 seconds from cardiovascular
disease (CVD) related deaths, resulting in about 655,000 deaths each year1, with racial
and ethnic groups disproportionately affected2. CVD is broadly defined as diseases
affecting the heart and blood vessels, including, but not limited to, coronary artery disease,
stroke, arrhythmia, heart attack, and heart valve problems. Of all the various types of CVD,
coronary artery disease (CAD)3 and heart attack significantly contribute to the overall
mortality associated with CVD4.

Despite sustained efforts to develop new treatments for heart failure, the prognosis
remains poor5. Over the past three decades, various treatment options, including the use
of angiotensin-converting-enzyme (ACE) inhibitors, beta-receptor blockers, aldosterone
antagonists, and stem cell therapies, have been utilized to manage heart failure6.
Unfortunately, despite the availability of these treatment options, no current treatment
cures heart failure but rather delays the progression of the disease. There is, therefore, a
need to explore other treatment options for heart failure by exploring the pathological
feature of the disease. Considering that metabolic alteration is a major contributor of heart
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failure6, treatments geared towards restoring altered metabolic pathways to improve heart
failure outcomes may significantly improve HF prognosis.

Metabolic Regulation of Heart failure
The heart requires an enormous amount of energy to sustain its contractile function6. To
do this, the heart relies on a variety of substrates including, fatty acids, glucose, ketones,
lactate, acetate, and branched-chain amino acids (BCAA), to generate ATP through
oxidative phosphorylation7. In the normal heart, most of the ATP is generated through the
oxidation of fatty acids8. However, during pathological remodeling, including heart failure
(pressure overload and myocardial infarction), the heart undergoes metabolic
reprogramming, characterized by increased reliance on glucose as its primary source for
ATP generation9-13. Although glucose uptake is increased during hypertrophy, capacity of
the mitochondria to utilize substrates is also impaired. Hence, both impaired mitochondrial
function and alterations in multiple metabolic pathways contribute to the accumulation of
various metabolites in the heart14-17, including C2-carnitine and acetyl-CoA, among
others18, 19. In addition to reduced capacity to oxidize fatty acids during heart failure, the
capacity of the heart to utilize ketones is increased20. Increased utilization of ketones can
promote accumulation of C2-carnitines20. It is speculated that chronic utilization of ketones
during heart failure leads to accumulation of acetyl-CoA and C2-carnitines more than the
mitochondria can oxidize20. Aberrant accumulation of metabolites can promote shunting
of these metabolites into other biological processes, including post-translational
modification of proteins (PTM). Interestingly, PTM of proteins have been implicated in the
pathogenesis of heart failure21-24.
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Post-Translational Modification and Heart failure
Post-translational modification (PTM) of cardiac proteins involves the covalent addition of
functional groups onto proteins. The addition of functional groups to proteins can alter their
overall tertiary structures, which can profoundly impact protein functions. For instance,
PTMs of proteins have been shown to be involved in physiological processes, including
protein-protein interactions, protein degradation, and gene expression25.

One possible way by which the mitochondria proteome is regulated is through PTM.
Various studies suggest that mitochondrial function is regulated by various PTMs,
including phosphorylation21, succinylation22, O-GlcNAcylation23, and acetylation24.
Furthermore, PTMs of mitochondrial proteins have been implicated in the progression of
CVDs. For example, studies show that phosphorylation of mitochondria complex IV
decreases oxidative phosphorylation by promoting destabilization of respirasomes
(supercomplexes)26. Similarly, multiple proteins and enzymes involved in glucose
oxidation, fatty acid oxidation, and respiratory complexes are subjected and regulated by
acetylation27, 28. Of the multiple types of PTM occurring during heart failure, acetylation
plays a major role in the pathophysiology of cardiovascular diseases. Alteration in cardiac
acetylation has been implicated in the development and progression of cardiovascular
diseases29. Interestingly, metabolic changes associated with cardiovascular disease
progression are linked to altered acetylation during HF. This dissertation provides an
overview of acetylation, and we sought to determine whether limiting aberrant
mitochondria acetylation is beneficial in the context of heart failure.

Acetylation
Acetylation is a modification that involved the addition of an acetyl group (CH3CO) on
molecules, including proteins. Since acetylation was discovered over 40 years ago30, 31,
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the concept of reversible protein acetylation as it relates to histone modification and
transcription of genes has been extensively studied32,

33

. Although earlier studies on

acetylation were focused on histone proteins, evidence of non-histone protein acetylation
has been reported34, 35. Emergence of high throughput techniques have revealed that a
vast number of non-histone proteins are subjected to acetylation, including multiple
cytosolic and mitochondrial enzymes36-38. Acetylation can occur co-translationally or posttranslationally. Co-translational modification usually occurs at the first a-amino group of
newly synthesized proteins and its termed N-a-acetylation. Furthermore, posttranslational modification occurring at the e-amino group of lysine residues is termed N-eacetylation39. Also, acetylation can occur in an enzyme dependent or independently
manner40 (Figure 1). A brief review of N-a-acetylation, N-e-acetylation, O-acetylation, and
enzyme independent acetylation is provided below:
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Figure 1: Schematic of the different types of acetylation. Acetylation can occur in
an enzyme dependent and independent fashion.
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N-a-acetylation
A vast majority of cytoplasmic eukaryotic proteins are subjected to N-a-acetylation. N-aacetylation is a non-reversible reaction catalyzed by a group of enzyme complexes known
as N-terminal acetyltransferases (NATs)41. NATs function by transferring an acetyl group
from its substrate, acetyl-CoA, to the first amino acid of newly synthesized proteins. The
addition of an acetyl group changes the chemical property of the N-terminus by
neutralizing its positive charge41. In eukaryotes, most of the N-a-acetylation is catalyzed
by various NATs, categorized as NatA, NatB, NatC, NatD, and NatE41. Although substrate
specificity of NATs has been described to be partially conserved in eukaryotes42-46, various
NATs can be differentiated by their subunit compositions41. For a detailed review of various
NATs, please refer to this review by Starheim et al.41. NATs regulate various cellular
processes including protein stability41, 47, protein-protein interaction41,

48-50

, and mediator

of protein complex formation51. Finally, N-a-acetylation is regulated by the availability of
acetyl-CoA41.

N-e-acetylation
Unlike N-a-acetylation that is non-reversible, N-e-acetylation involves a reversible transfer
of acetyl group from acetyl-CoA to the e-amino group of lysine residues. N-e-acetylation
reactions are catalyzed by lysine N-e-acetyltransferases (KATs), which were previously
known as histone acetyltransferases51. This reversible reaction is catalyzed by a group of
enzymes known as lysine deacetylases (KDACs), which comprises histone deacetylases
(HDACS) and sirtuins52. Mammalian KATs are generally classified based on their cellular
localization. Nuclear KATs are classified as type A, whereas cytoplasmic KATS are
classified as type B53. KDACs are classified into four major classes, including Class I-III,
sirtuins, and class IV HDACs54. For a detailed description of various classes of KATs and
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KDACs, particularly those involved in the cardiovascular system, please refer to the review
by Li et al53. Collectively, protein acetylation and deacetylation by KATs and KDACs are
crucial for regulating histones to influence gene transcription55.

O-acetylation
O-acetylation is another form of protein acetylation recently identified56, 57. In O-acetylation,
acetyl groups are transferred from acetyl-CoA to modify serine and threonine residues of
proteins57. Additionally, the extracellular matrix polysaccharides of plants, algae, bacteria,
and fungi are O-acetylated58. In bacteria (Yersinia pestis), Yersinia outer protein (YopJ)
catalyzes O-acetylation of serine and threonine residues of signaling proteins including,
MAPK/ERK kinase and IkappaB Kinase59. In plants, O-acetylation of various
polysaccharides is catalyzed by three families of proteins including the Trichromebirefringence-like (TBL), Altered xyloglucan 9 (AXY9), and Reduced wall O-acetylation
(RWA) family of proteins58. In humans, O-acetylation of sialic acid residue on gangliosides
by CAS1 domain-containing protein 1 (CASD1) has been reported60. Collectively, protein
modification by O-acetylation is thought to act in interplay with other forms of posttranslational modification such as phosphorylation to dynamically regulate protein function
in different organisms61; however, whether and to what extent mammalian cardiac proteins
are subjected to O-acetylation remains unknown.

Non-enzymatic acetylation
Unlike the other types of acetylation, non-enzymatic acetylation is not dependent on
enzymes. Mitochondrial proteins are particularly susceptible to non-enzymatic acetylation
due to their distinctive physiological property compared to other cellular compartments62.
First, compared to other cellular compartments, the pH of mitochondria is basic and is
maintained around 7.9—8.0 due to the extrusion of protons (H+) across the inner
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mitochondria membrane to generate proton motive force63. Secondly, being the site of
ATP generation, mitochondria generate between 0.1—1.5 mM of acetyl-CoA via cellular
oxidative phosphorylation64, 65. Studies have shown that high concentrations of acetyl-CoA
and the basic pH of the mitochondria can drive enzyme independent acetylation of
mitochondrial and non-mitochondrial proteins in vitro62,

66, 67

. Additional studies have

shown that mitochondria acetylation is primarily through a non-enzymatic mechanism68.
Thus, levels of acetyl-CoA can dictate mitochondrial acetylation state.

Crucial to sustaining this acetyl-CoA pool in the failing heart is the availability the acyl
group carrier, Coenzyme A (CoA)69. Synthesis of CoA from pantothenate is catalyzed by
pantothenate kinase (PanK), the rate-limiting enzyme in the CoA biosynthetic pathway70,
71

. CoA is abundant in the liver and heart and interestingly, these tissues have the highest

expression of PanK compared to other PanK isoforms—PanK2 and PanK372. Thus,
PanK1 is a primary, but not the sole, enzyme regulating CoA biosynthesis in the heart. In
summary, because mitochondrial acetylation is mostly enzyme independent and is
dependent on the availability of CoA, acetyl-CoA levels can be metabolically regulated by
the availability of CoA, creating an avenue to metabolically restrict acetyl-CoA level.

Role of cardiac acetylation
Acetylation in cardiac maturation, differentiation, proliferation, and in cardiac development
During the post-natal stage of cardiac maturation, the ability of the heart to switch from
glycolytic metabolism to fatty acid metabolism is crucial to support contractile activity of
the heart73. Although various factors have been implicated in regulation of cardiac
maturation, acetylation of non-histone proteins can regulate cardiac maturation74.
Fukushima et al.75 showed that general control of amino acid synthesis 5 like 1 (GCN5L1)
enzyme induced acetylation of long-chain acyl-CoA dehydrogenase (LCAD) and β-
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hydroxyacyl-CoA dehydrogenase (β-HAD) correlates with increased enzymatic activity
and fatty acid oxidation in newborns, suggesting a role of acetylation in fatty acid oxidation
maturation75. Interestingly, inhibition of hyperacetylation during cardiac maturation results
in delayed fatty acid oxidation and cardiac dysfunction76. Collectively, these studies
highlight the important role of acetylation during cardiac metabolic maturation.

Similarly, recent studies have highlighted the role of acetylation in the differentiation of
progenitor cells into cardiac cells. For instance, inhibition of histone deacetylase (HDAC)
by trichostatin A (TSA) treatment was sufficient to induce an increase in GATA-4
acetylation which promoted the expression of endogenous cardiac beta-myosin heavy
chain during embryonic stem (ES) cell differentiation77. Similarly, histone acetylation has
been shown to regulate islet-1 induced cardiac-specific differentiation of mesenchymal
stem cells (MSCs)78. In addition to its role in cardiac differentiation, acetylation was shown
to be important in cardiomyocyte proliferation. Sirtuin 1 (SIRT1) promotes the
deacetylation of p21 resulting in increased cardiomyocyte proliferation79, 80. Lastly, the
importance of acetylation in cardiac development was demonstrated by the embryonic
lethality and cardiac abnormality associated with SIRT1 deficiency in mice81. Collectively,
these studies emphasized the important role of cardiac acetylation during cardiac
maturation, differentiation, proliferation, and cardiac development.

Acetylation in contractile function
Acetylation has also been implicated in cardiac contraction through modulating the activity
of sarcomeric proteins. Reversible protein acetylation of cardiomyocyte sarcomeres
regulates its myofilament contractile activity82. Gupta et al. showed that a complex of
histone acetyltransferase, PCAF; and histone deacetylase, HDAC4 associates with the Zdisc and I- and A- band of cardiac sarcomeres and coordinate reversible acetylation of Z-
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disc-associated protein, MLP. Furthermore, studies demonstrated that increased
acetylation of myosin heavy chain isoform led to its increased enzymatic activity, thereby
enhancing its contractile dynamics83. Recently, a study demonstrated that acetylation of
cardiac troponin I (cTnl) can modulate its myofilament relaxation and sensitivity to
calcium84. Collectively, these various studies underscore the role of cardiac acetylation on
contractile proteins and its effect in regulating cardiac contraction.

Acetylation on mitochondrial function
Acetylation on fatty acid oxidation
Emerging studies utilizing advanced mass spectrometry techniques are revealing the
extent to which mitochondrial proteins are acetylated. Many mitochondrial enzymes (about
60%) involved in energy metabolism, including oxidative phosphorylation, electron
transport chain, and the TCA cycle, are acetylated85, 86. Although mitochondria acetylation
is mostly enzyme independent and is dependent on the availability of CoA, mitochondrial
acetylation can be regulated to a lesser extent, by some acyl transferases such as GNAT
family of acetyltransferases including general control of amino acid synthesis 5 like-1
(GCN5L1)87, 88 and acetyl-CoA acetyltransferase (ACAT1)89. Mitochondria acetylation has
been shown to regulate various aspects of fatty acid oxidation. For example, in cardiac
myocytes, acetylation was shown to activate the mitochondria fatty acid oxidation enzyme,
enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase90. Similarly, acetylation of
mitochondrial fatty acid oxidation enzyme, long-chain acyl-CoA dehydrogenase (LCAD),
and β-hydroxyacyl-CoA dehydrogenase (β-HAD) is associated with increased enzyme
activity and fatty acid oxidation in conditions of excess nutrient90,
acetylation plays important role in regulating fatty acid oxidation.
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91

. Collectively,

Acetylation on mitochondria biogenesis, autophagy, and mitophagy
Acetylation of mitochondria proteins has also been implicated in mitochondria biogenesis
regulation. Mitochondria biogenesis is the process by which cells increase their
mitochondria number through the division of already existing mitochondria. Mitochondria
biogenesis is regulated by nuclear-encoded peroxisome proliferator-activated receptorgamma coactivator 1- alpha (PGC1A)92. In the heart and skeletal muscles, PGC1A is
highly expressed and transcribes genes encoding mitochondria proteins involved in a
variety of processes including oxidative phosphorylation, citric acid cycle (CAC), and fatty
acid oxidation92. Studies have shown that acetylation regulates PGC1A. SIRT1, a protein
deacetylase, can activate PGC1A to regulate exercise-induced mitochondria biogenesis93,
94

. Collectively, this study suggests the role of acetylation in regulating mitochondria

biogenesis. Similarly, studies have shown that acetylation of mitochondria protein
regulates autophagy and mitophagy. Studies have shown that in neonatal mouse
cardiomyocytes, SIRT3 can regulate mitophagy and autophagy through diacylation of
FOXO3a and PARKIN95. In summary, acetylation can regulate mitochondria dynamics
through the regulation of mitochondria biogenesis and mitophagy.

Acetylation on mitochondria respirasomes (supercomplexes)
Mitochondria are responsible for providing energy for cardiac contraction96, 97. A decline in
mitochondrial function is a major contributor to the pathogenesis of HF. Mitochondrial
electron transport is organized into supercomplexes98 and supercomplex assembly
impacts bioenergetics99. Studies have shown that mitochondrial supercomplexes
composition is changed during heart failure99, but the mechanism of how this occurs is
unknown. Many mitochondrial enzymes in the electron transport chain are acetylated. For
instance, studies have shown that complex II hyperacetylation was shown to reduce
complex II activity100. Similarly, in the failing heart, acetylation of SDHA correlated with
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decreased complex II activity and complex II-mediated respiration101. In addition, during
heart failure, several subunits of Complex III and Complex IV were found to be acetylated
in murine model of heart failure. Although studies have shown that phosphorylation of
specific subunits of complex IV causes destabilization of supercomplexes26, the extent to
which acetylation promotes destabilization of the supercomplexes has not been
elucidated. One of the aims of this dissertation is to address the extent to which changing
acetylation levels impact supercomplexes.

Acetylation in cardiovascular disease
Acetylation in cardiac hypertrophy
One way by which the heart adapts to increased workload as a result of a physiological or
pathological signal is hypertrophy102. Although several studies have investigated the
numerous ways by which physiological and pathological cardiac hypertrophy is regulated,
there is evidence suggesting that acetylation plays an important role in regulating
pathological cardiac hypertrophy. Signatures of pathological hypertrophy include
disassembly

of

sarcomeric

structure,

increased

protein

synthesis,

increased

cardiomyocyte size, reactivation of cardiomyocyte fetal gene expression103. Since one of
the pathological features of cardiac hypertrophy is fetal gene reprogramming, histone
acetyltransferases and deacetylases play an important role in this process. For instance,
a histone acetyltransferase (HAT), p300, has been shown to regulate hypertrophy through
interacting with transcriptional factors GATA4 and MEF2104, 105. Acetylation of GATA4 and
MEF2 by P300 can enhance the binding of these transcriptional factors on the DNA to
promote the expression of pathological genes associated with cardiac hypertrophy104, 106.
Also, histone deacetylases were implicated in regulating cardiac hypertrophy. Studies
have shown that SIRT3 deletion exacerbates cardiac hypertrophy in response to
increased workload107, suggesting that SIRT3 plays an important role in regulating cardiac
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hypertrophy. Similarly, studies showed that SIRT2 expression is downregulated in
hypertrophic heart, and SIRT2 knockout promotes cardiac hypertrophy while expression
of SIRT2 protects against cardiac hypertrophy108. Contrary to the role of SIRT2 and SIRT3
in regulating cardiac hypertrophy, SIRT4 deficiency suppresses prevents hypertrophic
growth109. Collectively, these data emphasize the differential role of acetyltransferases
and deacetylases in regulating cardiac hypertrophy and open questions about specific
protein targets of each deacetylase.

Acetylation in cardiac fibrosis
In the injured heart, cardiac fibroblasts become activated into myofibroblasts and are
responsible for cardiac fibrosis110. Myofibroblasts are characteristically highly proliferative
and are involved in synthesizing extracellular matrix (ECM) components. Studies have
suggested the role of acetylation in the development of cardiac fibrosis. Cardiac fibroblast
isolated from murine fibroblast model of congestive heart failure was shown to have
increased expression of HDAC1111. Interestingly, the administration of an HDAC inhibitor
was sufficient to prevent fibroblast proliferation, activation, and induce apoptosis112.
Similarly, HDAC4 knockdown in human cardiac fibroblast was sufficient to inhibit
differentiation of naïve fibroblast into myofibroblast113. Furthermore, SIRT2 and SIRT3
deletion in mice exacerbated cardiac fibrosis in response to angiotensin II treatment114, 115.
These studies suggest a role of acetylation in regulating cardiac fibrosis. Further research
is warranted to fully understand the mechanisms of how acetylation regulates fibroblast
function in the context of heart failure.

Acetylation in ischemia/reperfusion (I/R) injury
Ischemia/reperfusion injury significantly contributes to mortality following myocardial
infarction (MI)116. Although the pathophysiology of I/R injury is complex and involves
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multiple cellular processes, including apoptosis, autophagy, inflammation, and
mitochondrial dysfunction 117, studies have implicated the role of acetylation in contributing
to I/R injury. Manning et al. showed that deletion of GCN5L1, an acyltransferase involved
in mitochondrial acetylation, resulted in exacerbated myocardial post-ischemic functions
118

, suggesting a protective role of acetylation induced by GCN5L1 in I/R injury. In support

of the idea that increasing acetylation is beneficial in the context of I/R injury, Zhao et al.
reported that suppressing HDACs by trichostatin (TSA) treatment was sufficient to confer
cardioprotection partly by reducing myocardial infarct size119. Additionally, deletion of
SIRT3 exacerbated cardiac response to I/R by affecting mitochondrial function100, 120. In
summary, regulation of cardiac acetylation plays a significant role in outcomes following
I/R injury.

Acetylation in hypertension
Hypertension is a great risk factor for the development of CVD100. Studies have shown
that acetylation can mediate both mitochondrial and histones to regulate the development
of hypertension. For instance, in a model of deoxycorticosterone acetate (DOCA)-salt
hypertensive rats, HDAC inhibition increased acetylation of mineralocorticoid receptor and
reduced its binding affinity to responsive elements of its hormones, resulting to blunted
recruitment of RNA polymerase and significant repression of genes modulating
intracellular salt balance121, 122, suggesting a role of acetylation in regulating hypertension.
Similarly, deletion of SIRT3, a mitochondrial-specific deacetylase, promoted the
development of hypertension and resulted in increased production of mitochondrial
superoxide radicals123. Collectively, these studies underscore the role of acetylation in the
development of hypertension.
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Targeting acetylation as a treatment for HF
Because acetylation can impact the development and progression of CVD, several
treatment options have been developed to manage the progression of cardiovascular
diseases through targeting acetylation. First, several histone deacylated (HDAC) inhibitors
are in the clinical phase to manage cardiovascular diseases53. Different classes of histone
deacetylases such as hydroxamic acids (trichostatin A, tubastatin A, and vorinostat),
benzamines (mocetinostat and entinostat), short-chain fatty acids (valproic acid and
sodium butyrate) have been used in animal models of various CVD53. Similarly, sirtuin
inhibitors have also been used in animal models of CVD, and they include acylamide and
β-naphthol. For a full review of acetylation inhibitors used in cardiovascular disease,
please refer to a review by Li et al.53. Lastly, the use of angiotensin-converting-enzyme
(ACE) inhibitors, beta-receptor blockers, aldosterone antagonists, and stem cell therapies,
have been utilized to manage heart failure6. Unfortunately, despite the availability of these
treatment options, no current treatment cures heart failure but rather delay the progression
of the disease. There is, therefore, a need to explore other treatment options for heart
failure by exploring the pathological feature of the disease. Considering that metabolic
alteration is a major contributor of heart failure6, treatments geared towards restoring
altered metabolism to improve heart failure outcomes may significantly increase HF
prognosis.

Summary and gap in knowledge
Acetylation plays vital role in regulating normal cardiac function and can impact the
development and progression of CVD, leading to heart failure related mortality. Although
several treatment options targeting acetylation are available to treat heart failure, none of
these treatments have made tremendous impact on heart failure prognosis. Although
Some of these available therapy targets multiple cellular and molecular cardiac processes,
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multiple lines of evidence suggest that metabolic derangement coupled with mitochondrial
dysfunction are major contributors of heart failure6,

14-17

. Considering that metabolic

alteration is a major contributor of heart failure, treatments geared towards restoring
altered metabolic pathways to improve heart failure outcomes seems like a viable
treatment option for heart failure that is currently underexplored. Hence, strategies
targeting aberrant metabolic processes in the context of heart failure may significantly
improve overall cardiac function and survival.

Additionally, dysregulated metabolism can promote post translational modification of
mitochondrial proteins by acetylation. Recent studies have shown that hyperacetylation of
mitochondrial proteins is associated with a decline in mitochondrial function. Furthermore,
mitochondrial respirasome (supercomplex) composition is changed during HF and may
affect mitochondria efficiency. Despite these general, coincidental associations, it is not
known whether acetylation directly regulates mitochondrial supercomplexes and
bioenergetics. Considering that the heart requires enormous amount of ATP to carry out
its contractile activity, studies aimed at identifying additional mechanisms by which
mitochondria supercomplexes are regulated may provide a new therapy for repairing
mitochondrial dysfunction during heart failure.

In this project, we utilize a metabolic approach to target metabolically driven acetyl-CoA
in the failing heart. Because accumulated acetyl-CoA can drive enzyme independent
acetylation of mitochondria protein to promote cardiac and mitochondrial dysfunction, we
tested the idea that targeting aberrant metabolite accumulation (acetyl-CoA) may be a
novel and viable option treating heart failure.
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CHAPTER II
HYPOTHESIS AND SPECIFIC AIMS
Significant metabolic changes occur during heart failure (HF). Such metabolic changes
are not simply associated with HF; they also likely contribute to the pathophysiology.
Among the various metabolic changes, studies have shown that acetyl-CoA levels are
elevated in the failing heart. Elevated acetyl-CoA levels may drive enzyme-independent
hyperacetylation of proteins (particularly mitochondrial). Recent studies have shown that
hyperacetylation of mitochondrial proteins is associated with a decline in mitochondrial
function. Furthermore, mitochondrial respirasome (supercomplex) composition is changed
during HF and may affect mitochondria efficiency. Despite these general, coincidental
associations, it is not known whether limiting mitochondria acetylation will be beneficial in
HF and whether such an intervention rescues respirasome assembly after HF. Thus, this
project will identify the role of reduced mitochondrial acetylation in HF and will elucidate
how changes in mitochondrial acetylation impact mitochondrial function and respirasome
assembly. We will limit mitochondrial acetylation in HF by using pantothenate kinase 1
deficient mouse (Pank1-/-) which, according to our preliminary data have reduced CoA
levels and reduced mitochondrial acetylation. Because recent studies have shown that HF
increases acetyl-CoA levels, which drives mitochondrial hyperacetylation and may
exacerbate ventricular dysfunction, I predict that reduced mitochondrial acetylation will
improve function of the failing heart by rescuing mitochondrial function via restoration of
mitochondrial respirasome assembly. This hypothesis will be tested by the following
Specific Aims:
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Specific Aim 1: Determine whether limiting mitochondria acetylation via restricting
CoA affects basal bioenergetics: The effect of limiting acetylation on basal mitochondria
and cardiac function will be studied using mitochondria isolated from Pank1-/- mice. I will
assess total cardiac and mitochondria acetylation levels in Pank1-/- mice. I will assess the
effect of limiting mitochondria acetylation on mitochondria abundance and cardiac function
in Pank1-/- mice. Similarly, I will assess mitochondria bioenergetics using extracellular flux
analysis (XF). Using mass spectrometry, I will identify mitochondrial proteins differentially
acetylated as a result of limiting CoA levels.

Specific Aim 2: Determine whether reduced mitochondrial hyperacetylation is
beneficial during HF. Hypothesis: Limiting CoA biosynthesis will reduce mitochondrial
acetylation and improve cardiac function in the failing heart. The role of reduced
mitochondrial acetylation in heart failure will be studied using our established model of HF.
Endpoints of ventricular function and cardiac remodeling will be assessed in
cardiomyocyte-specific Pank1 deficient mice (cmPank1-/-) post-infarct hearts. I expect to
observe improved ventricular function in cmPank1-/- mice compared to WT littermates.

Specific Aim 3: Elucidate the impact of mitochondrial acetylation on mitochondrial
bioenergetics in the context of HF. Hypothesis: Mitochondrial hyperacetylation
negatively regulates mitochondrial function and respirasome assembly. I will characterize
cardiac and mitochondrial acetylation status after MI. I will also assess changes and
composition of mitochondrial supercomplex after MI using BN-PAGE and mass
spectrometry, respectively. Also, I will assess the impact of mitochondrial acetylation on
cardiomyocyte bioenergetics (using cardiomyocytes isolated from post-MI, cmPank1-/mouse hearts). Similarly, I will assess the impact of mitochondrial acetylation on
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respirasome assembly using mitochondria isolated from Pank1-/- hearts following MI. I
expect to rescue mitochondrial function with decreasing acetylation.

We will use a metabolism-centered intervention to generate proof-of-concept observations
that limiting CoA biosynthesis will limit the driving force for mitochondrial acetylation. This
project will enhance our understanding of the impact of mitochondrial acetylation on
bioenergetics in the failing heart and will establish whether reducing mitochondria
acetylation will improve mitochondrial function during heart failure. This project could
identify a novel target for heart failure.
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CHAPTER III
MATERIALS AND METHODS
All animals were used in compliance with the Guide for the Care and Use of Laboratory
Animals issued by the National Institutes of Health. The experimental protocols in this
study have been reviewed and approved by the University of Louisville Institutional Animal
Care and Use Committee. Well-characterized, de-identified human myocardial tissue
samples were obtained from the Transplantation Biobank of the Heart and Vascular
Center at Semmelweis University, Budapest, Hungary124. The procedure of sample
procurement was reviewed and approved by the institutional and national ethics
committee (ethical permission numbers: ETT TUKEB 7891/2012/EKU (119/PI/12.) and
ETT TUKEB IV/10161-1/2020/EKU). Informed consent was obtained from patients in line
with the Declaration of Helsinki prior to sample collection. In all cases, myocardial samples
were surgically removed and immediately snap-frozen in liquid nitrogen under sterile
conditions. Non-failing control left ventricular (LV) myocardial samples were isolated from
LV papillary muscles removed from patients undergoing mitral valve replacement.
Myocardial LV samples from end-stage heart failure patients were collected during heart
transplantation.
Generation of constitutive, cardiac specific Pank1-deficient mice (cmPank1-/-): To
create cmPank1-/- mice, we crossed Pank1-floxed mice125,
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with constitutive,

cardiomyocyte-specific Cre (Myh6-Cre) transgenic mice (Stock #011038, The Jackson
Laboratory). Whole body PanK1 deficient mice (Pank1-/-) were also used126. All animals
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used in this study were on a C57BL6/J background. Male and female mice were used in
this study.

Transverse aortic constriction surgery: 12-16 wk old cmPank1-/- mice and their wildtype littermates (cmPank1+/+) were subjected to transverse aortic constriction (TAC), as
previously described127, 128, 129, 130. Briefly, mice were anesthetized intraperitoneally with
ketamine (50 mg/kg) and pentobarbital (50 mg/kg). Next, anesthetized mice were then
orally intubated with a polyethylene-60 tubing and ventilated (Harvard Apparatus Rodent
Ventilator, model 845) with oxygen supplementation. Mice were maintained under
anesthesia with an isoflurane vaporizer (1%) supplemented with 100% oxygen. The aorta
was visualized through an intercostal incision, and a 7-0 nylon suture was looped around
the aorta between the brachiocephalic and left common carotid arteries. The suture was
tied around a 27-gauge needle to constrict the aorta to a reproducible diameter. Then the
needle was removed, leaving a discrete region of stenosis (TAC mice). Following stenosis,
the chest was closed, mice were extubated upon recovery of spontaneous breathing and
were allowed to recover in warm, clean cages. Analgesia (ketoprofen, 5 mg/kg,
subcutaneous) was given before mice recovered from anesthesia (and by 24 and 48 h
later). At the appropriate time point (i.e., 2 and 12 wk post TAC), mice were euthanized,
and the hearts were snap-frozen in liquid nitrogen for qPCR, RNA-sequencing, and
metabolomics analysis. The surgeon was blinded to the genotype of each mouse.

Echocardiography: Transthoracic echocardiography of the left ventricle was performed
similarly to previously described methods14, 131-135 at 2, 4, 8, and 12 wk post TAC, except
that here a VisualSonics Vevo 3100 was used in the present study. The sonographer was
blinded to the treatment group.
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RNA-sequencing: Total RNA was isolated from cardiac tissue as previously described136138

. RNA was quantified and assessed using NanoDrop ONEC (Thermo Scientific) and at

least 10 µg of RNA was sent to Novogene Corporation Inc. for RNA-sequencing. For data
analysis, FASTQ files were trimmed using fastp139 (version 0.20.0) using the following
parameters:
--cut_by_quality5

--cut_by_quality3

--detect_adapter_for_pe

--

overrepresentation_analysis --correction --trim_front1 7 --trim_front2 7. Alignment
to the mouse genome (GRCm38.90) was performed using STAR140 (version
020201) with the following parameters: --runMode alignReads --runThreadN 8 -outSAMstrandField intronMotif --outSAMmode Full --outSAMattributes All141, 142 -outSAMattrRGline {params.readgroup} 143 --outSAMtype BAM SortedByCoordinat
--limitBAMsortRAM

45000000000

--quantMode

GeneCounts

--

outReadsUnmapped Fastx -outSAMunmapped Within {params.keepPairs}.
Differential expression analysis was performed using edgeR144 (version 3.10). The RLE
(relative log expression) method was used to normalize the data. Heat maps were
generated using multiviewer (MeV) software as previously described145. Finally, volcano
plots were generated using OriginPro, version 2020. (OriginLab Corporation, MA, USA).
Differentially regulated genes at a threshold of 2-fold change and a p-value <0.05 were
considered significant for all RNA-seq analyses used for this study.

Determination of CoA levels: To determine cardiac-specific depletion of CoA levels,
heart and skeletal muscle from naïve cmPank1+/+ and cmPank1-/- mice were freezeclamped with Wollenberger forceps and snap-frozen in liquid nitrogen. Samples were
stored frozen (–80°C) until CoA extraction was performed. Determination of free CoA and
CoA thioesters were performed by HPLC as previously described146. Briefly, frozen tissue
was homogenized and resuspended in cold water (2 ml). Next, 500 µl of 250mM KOH was
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added to homogenized cardiac tissue. Next, CoA was derivatized with monobromobimane
(mBBr) (Life Technologies) and quantified by reverse-phase HPLC by utilizing a Gemini
C18 3 µm column (150 X 4.60 mm) (Phenomenex). For the HPLC run, 50 mM potassium
phosphate (pH 4.6) was used as solvent A and 100% acetonitrile was used as solvent B.
20 µl of samples was injected on the column and the flow rate was set at 0.5 ml/min. After
the HPLC run, the elution position ofmBBr-CoA, mBBr-dephospho-CoA (deP-CoA), and
mBBr-phosphopantrtheine (PPanSH) were compared to known standards.

Metabolomics
described147,

analysis:

148

Metabolomic

analysis

was

performed

as

previously

. Briefly, after anesthesia, hearts were snap-frozen in liquid nitrogen,

pulverized, and sent to Metabolon Inc. for untargeted metabolite analysis by LC-MS.
Analyses

of

metabolites

were

performed

using

MetaboAnalyst

4.0

software

(http://www.metaboanalyst.ca/). Differentially regulated metabolites at a threshold of 1.5fold change and a p-value <0.05 were considered significant for all analyses used for this
study.

Reverse transcriptase PCR and real-time PCR: Total cardiac RNA was extracted and
used to make cDNA as described previously136-138. The relative levels of mRNA transcripts
were quantified by real-time PCR using Power SYBR Green (Thermo Fisher Scientific) on
a real-time PCR system (ViiA 7, Applied Biosystems). Most primers were made using
NCBI Primer Blast except HPRT primers (PPM03559E-200, QIAGEN). The data were
normalized to mouse HPRT mRNA threshold cycle (CT) values by using the ΔΔCT
comparative method.

Protein isolation: Total cardiac protein was isolated as previously described149. We
determined cardiac lysate protein concentration by the Bradford assay with a protein
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assay dye (Bio-Rad, catalog #5000006) using different concentrations (0, 1, 2, 4, and 8
mg/ml) of bovine serum albumin as standards. We measured protein concentrations using
a Thermo Multiskan Spectrum spectrophotometer.

Immunoblotting: Total cardiac protein samples were loaded on an SDS-PAGE gel and
subjected to electrophoresis at 150 V for 1 h. Next, SDS-PAGE resolved proteins were
transferred onto PVDF membrane (Immobilon-P, EMD Millipore, Billerica, MA, USA). For
acetylation blots, membranes were blocked for 1 h at room temperature using TBS-T
(washed with TBS containing Tween-20) containing 5% BSA. Next, membranes were
probed with acetylated-lysine mouse mAb (1:1000, Cell signaling #9681) primary antibody
and incubated overnight at 4°C. The next day, membranes were washed three times using
TBS-T. Membranes were blocked using 5% BSA for 1 h at room temperature followed by
incubation with anti-mouse IgG, HRP-linked (1:1000. Cell signaling #7076S) secondary
antibody. Finally, membranes were washed three times at 10 min each time with TBS-T.
The membrane was saturated with SuperSignal West Pico Chemiluminescent Substrate
(Thermo Fisher Scientific) and imaged on a Fuji LAS-3000 bio-imaging analyzer. To
confirm the linear range of the signal, multiple exposures from every experiment were
performed. Levels of proteins in each lane were normalized to loading protein content (αtubulin or to Ponceau stain and expressed as relative to control (set as 100%). All other
western blots follow standard protocols as described130. Pank1 expression was
determined using a PANK1 antibody (1:1000), which was generated as previously
described150.

Mitochondria Isolation: Mitochondria was isolated from heart tissues as previously
described151. Briefly, heart tissues from WT C57BL6/J, cmPanK1+/+, cmPanK1-/-, PanK1+/+,
PanK1-/-, or human biopsy were homogenized using a Potter Elvehjem tube and a Teflon
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pestle containing 1.2 ml of isolation buffer (Buffer A: 220 mM mannitol, 70 mM sucrose,
5 mM MOPS, 1 mM EGTA, 0.2% fatty acid-free BSA, pH 7.2). Homogenates were
transferred to a 1 ml tube and centrifuged at 800g for 10 min at 4°C. After centrifugation,
supernatants were collected into a clean 1 ml tube and centrifuged at 10,000g for 15 min at
4°C to obtain mitochondrial pellets. Mitochondrial pellets were then washed twice in 1 ml
of isolation buffer and then resuspended in 400 μL respiration buffer (120 mM KCl, 25 mM
sucrose, 10 mM HEPES, 1 mM MgCl2, 5 mM KH2PO4, pH 7.2). Protein concentration was
assessed using the Lowry DC Protein Assay kit (Biorad), and mitochondrial were used for
downstream analysis by extracellular flux analysis, blue native PAGE (BN-PAGE) gel, and
western blot analysis.

Measurement of mitochondrial bioenergetics: We assessed mitochondrial respiration
using XF24 analyzer (Agilent), as previously described152-154. Briefly, 5 μg of mitochondrial
protein was suspended in 50 μL of respiration buffer and loaded into 24-well XF culture
microplates. Next, loaded microplates were then centrifuged at 500g for 3 min at 4 °C,
followed by the addition of 625 μL of warm (37 °C) respiration buffer. Pyruvate (5 mM),
malate (2.5 mM) and , ADP (1 mM) (PMA); succinate (5 mM), rotenone (1 μM) and, ADP
(1 mM) (SRA); or octanoyl-l-carnitine (100 μM), malate (2.5 mM) and, ADP (1 mM) (PMA)
were used to stimulated state 3 respiration in the presence of the following inhibitors:
oligomycin (1 μM ), FCCP (1 μM), and antimycin A+rotenone (AA/Rot; 10 μM/1 μM).

Blue-native PAGE (BN-PAGE): BN-PAGE was performed as previously described155.
Briefly, isolated mitochondria pellets were solubilized in digitonin buffer containing 1:100
protease inhibitor cocktail (Sigma). Next, solubilized mitochondria were centrifuged at
16,000g for 15 min at 4°C. The supernatant was collected and separated on BN-PAGE
gels. BN-PAGE gels were prepared using polyacrylamide (acrylamide:bis-acrylamide,
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37.5:1) at either a 5–15% or a 3–12% gradient. The cathode buffers used contained 50
mM Tricine, 15 mM Bis-Tris, pH 7.0, and 0.02% Coomassie Blue G250 (high blue buffer)
or 0.004% Coomassie Blue (low blue buffer). The anode buffer consisted of 50 mM BisTris pH 7.0. Electrophoresis was performed at 4°C using a high blue buffer at 100 V for 1
h, followed by low blue buffer at 250 V for 1.5 h. For assessing supercomplex abundance
in Coomassie-stained gels, we loaded 70 µg mitochondrial protein per lane.

Electron Microscopy: Analysis of cardiac ultrastructure by electron microscopy was
carried out as previously described with modifications152. Briefly, cardiac tissue was
dissected into 3-mm3 pieces and fixed in a solution containing 2% paraformaldehyde and
2% glutaraldehyde for two days. The samples were then post fixed in 1% osmium tetroxide
in 0.1 M phosphate buffer, dehydrated in ascending concentrations of ethanol, embedded
in Durcopan resin (Sigma-Aldrich), sectioned, and mounted on 100-mesh copper grids.
Lastly, mounted sections were doubly stained with uranyl acetate and lead citrate.
Ultrastructure was examined by using a Hitachi HT7700 electron microscope operating at
80 kV.

Pathology: Following final echocardiography, hearts were excised and arrested in
diastole with 2% KCl. Hearts were then sectioned into 1 mm short-axis sections. A midventricular section was fixed with 10% formalin; the samples were subsequently
embedded, cut, and mounted. Later, the slides were deparaffinized and rehydrated as
needed for the appropriate stain. All fluorescent and brightfield images were captured
using the Keyence BZ-X810, all-in-one fluorescent microscope. Acquired images were
analyzed using the hybrid cell count feature (BZ-H4C). For WGA analysis using the
Keyence, MATLAB version 9.7.01216025 (R2019b) was used to compile data files
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exported from the Keyence analysis software to generate a summary file for data analysis,
and the microscopist was blinded to group assignment.
Cardiomyocyte hypertrophy – Cardiac sections were stained with wheat germ agglutinin
(WGA; AlexaFluor 555 conjugate; Invitrogen) to identify cell borders and stained with DAPI
to detect nuclei. WGA-stained cells were visualized using a fluorescent microscope BZX810 (Keyence). Cardiomyocytes were chosen based on a circularity greater than 0.5 and
whether they had centrally located nuclei. Circularity was calculated using: (4*π
*area)/(perimeter)2.
Vascular density – Cardiac sections were stained with isolectin B4 (fluorescein labeled
Griffonia simplicifolia Lectin I; Vector Labs) as we have described previously138. Vascular
density was determined as the number of capillaries per area of tissue (number of
capillaries per mm2). A circularity threshold of 0.3 was applied to eliminate all capillaries
that are not in cross section and to ensure uniformity.
Cardiac fibrosis – Cardiac sections were stained with Masson’s trichrome stain to
determine fibrosis and total collagen content according to published protocols156-158.
Fibrosis was expressed as a percentage of as scar tissue to the total area of short axis
LV tissue.
Apoptosis – Cardiac sections were stained using a TUNEL assay (DeadEnd™
Fluorometric TUNEL System, Promega) to detect DNA fragments and counterstained with
DAPI (VECTASHIELD® PLUS Antifade Mounting Medium with DAPI, Vector
Laboratories) to identify nuclei. Counted fragmented DNA were compared to the number
of nuclei present to determine the percentage of TUNEL positive cells. Signal less than 20
µm2 and a circularity threshold less than 0.5 were excluded to promote consistency and
to ensure that nuclei being counted were in cross-section and the signal being identified
was not background. Finally, the counted fragmented DNA were compared to the number
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of nuclei present to determine the percentage of cells that are TUNEL positive or
considered to be apoptotic.

Statistical analysis: Results are shown as mean ± SD. Statistical analysis was conducted
using a one-tailed Student’s t test to compare two groups. All statistical analyses were
performed using GraphPad Prism, version 9 (GraphPad Software, La Jolla, California)
and MetaboAnalyst (http://www.metaboanalyst.ca/). Differences were considered
statistically significant if p<0.05.
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CHAPTER IV
RESULTS
Results for Specific Aim 1
Limiting mitochondrial acetylation does not affect basal mitochondrial dynamics and
bioenergetics.
Because both N-a- and N-e-acetylation depends on availability of acetyl-CoA, and
synthesis of acetyl-CoA is partly dependent on the availability of an acyl carrier—
coenzyme A (CoA)39, we sought to reduce CoA levels via Pank1 deletion—as an
intervention to suppress metabolically accumulated acetyl-CoA. First, we assessed the
impact of limiting mitochondrial acetylation on basal mitochondrial bioenergetics by
utilizing whole body pantothenate kinase 1 deficient mouse (Pank1-/-). Pank1 deletion
resulted in a significant reduction in cardiac Pank1 mRNA (Figure 2B), protein (Figure 2C),
and CoA reduction (Figure 2 D). As predicted, mitochondria isolated from whole body KO
(Pank1-/-) have significantly reduced mitochondrial acetylation compared to their WT
littermates (Pank1+/+) (Figure 3).
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Next, we assessed the impact of limiting mitochondria acetylation on mitochondrial
biogenesis and dynamics. We did not observe any significant difference in markers of
mitochondrial biogenesis, which includes mRNA expression of Pgc1b and Nrf1 in
mitochondria isolated from Pank1-/- hearts (Figure 4A and B). Furthermore, we did not
observe any difference in mitochondrial abundance (Figure 4C). Additionally, we assessed
the impact of reducing mitochondrial acetylation on respiratory function by extracellular
flux analysis. Compared to Pank1+/+, limiting mitochondria acetylation does not impact
state 3 and 4 respiration in the presence of complex I (pyruvate, malate, and ADP)
substrates (Figure 4D). Collectively, these data suggest that limiting mitochondria
acetylation does not affect basal mitochondrial biogenesis, dynamics, and mitochondrial
function. Given these observations, we then sought to determine whether limiting
mitochondrial acetylation will be beneficial during heart failure.
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Specific Aim 2
Cardiac specific pantothenate kinase 1 deletion (cmPank1-/-) limited coenzyme A (CoA)
availability.
To study whether limiting mitochondria acetylation (through CoA depletion) is beneficial in
heart failure, we generated a cardiomyocyte specific Pank1 deficient mice (cmPank1-/-).
To generate cmPank1-/- mice, we crossed Pank1-floxed mice with constitutive,
cardiomyocyte-specific Cre (Myh6-Cre) transgenic mice, such that control mice
(cmPank1+/+) were Myh6-Cre-negative/Pank1fl/fl and our cardiomyocyte-specific Pank1
deficient mice (cmPank1-/-) were Myh6-Cre-positive/Pank1fl/fl. In cmPank1-/- hearts,
PANK1 mRNA levels, but not PANK2 or PANK3, were significantly decreased in the hearts
compared to WT littermates (lacking the Myh6-Cre transgene; cmPank1+/+) (Figure 5A).
Consistent with decreased mRNA in cmPank1-/- hearts, PANK1 protein was significantly
decreased in cmPank1-/- compared to cmPank1+/+ hearts (Figure 5B). Furthermore,
consistent with changes in PANK1 mRNA and protein, coenzyme A (CoA) levels were
significantly lower in cmPank1-/-, compared to cmPank1+/+ hearts, and not the skeletal
muscle (Figure 5C), confirming that CoA depletion is restricted to the heart. Because CoA
is abundant in the mitochondria, we examined the impact of Pank1 deletion on
mitochondria acetylation. As expected, PANK1 deletion resulted to significant reduction in
mitochondria acetylation at baseline (Figure 5D and 5E).
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Figure 6: Cardiomyocyte specific Pank1 deletion limits cardiac mitochondria acetylation. We characterized the impact of cardiomyocyte
Pank1 deletion on cardiac mitochondrial acetylation. A) Cardiac Pank mRNA expression. B) Cardiac PANK1 protein expression. C) CoA levels in
Figure
5: Cardiomyocyte specific Pank1 deletion limits cardiac mitochondria
the heart and skeletal muscle. D) Mitochondria acetylation levels via immunoblot. E) Quantification of acetylation levels at indicated molecular
weights. An unpaired Student’s t test was used to determine significant differences between cmPank1+/+ and cmPank1-/- groups.

acetylation. We characterized the impact of cardiomyocyte Pank1 deletion on cardiac
mitochondrial acetylation. A) Cardiac Pank mRNA expression. B) Cardiac PANK1 protein
expression. C) CoA levels in the heart and skeletal muscle. D) Mitochondria acetylation
levels via immunoblot. E) Quantification of acetylation levels at indicated molecular
weights. An unpaired Student’s t test was used to determine significant differences
between cmPank1+/+ and cmPank1-/- groups.
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cmPank1 deletion minimally affected cardiac function, structure, and global gene
expression at baseline.
To determine the impact of Pank1 deletion on baseline cardiac function, 12-16-week-old
cmPank1-/- and cmPank1+/+ mice were subjected to echocardiography, and endpoints of
cardiac function were assessed. Compared to cmPank1+/+, heart rate (HR), stroke volume
(SV), left ventricular end-diastolic (EDV) and systolic (ESV) volumes, cardiac output (CO),
left ventricular inner diastolic (LVIDd), and systolic (LVIDs) diameter, left ventricular
posterior wall thickness at diastole (LVPWd) and systole (LVPWDs), left ventricular
anterior wall thickness at systole (LVAWDs) were not significantly changed in cmPank1-/compared to cmPank1+/+ (Table 1; Figure 6A and 6B). Ejection fraction (EF) was
significantly reduced in cmPank1-/- compared to cmPank1+/+ hearts in a sex-dependent
manner (Figure 6C; Table 2). Furthermore, left ventricular anterior wall thickness at
diastole (LVAWd) was significantly reduced in cmPank1-/- compared to cmPank1+/+ hearts
(Table 2). Collectively, these data suggest that Pank1 deletion minimally affected basal
cardiac function in naïve mice.

Next, we assessed the impact of Pank1 deletion on cardiac fibrosis and vascular density
at baseline by trichrome staining and isolectin B4 staining. Total fibrosis and vascular
density were not changed as a result of Pank1 deletion (Figure 6D-G).
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Table 1: Gravimetric and echocardiographic data from naïve 12-16 wk old mice
*p<0.05 when we compare cmPank1-/- vs cmPank1+/+.
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Figure 6: Cardiomyocyte specific Pank1 deletion does not affect ventricular size,
fibrosis, and vascular density in naïve mice hearts. A) End diastolic function (EDV). B)
End systolic function (ESV). C) Ejection fraction (EF). D) Trichrome stained hearts. E)
Quantification of fibrosis in trichrome stained hearts. F) Isolectin B4 (green) stained hearts
to determine vascular density. G) Quantification of vascular density in isolectin B4 stained
hearts. An unpaired Student’s t test was used to determine significant differences between
cmPank1+/+ and cmPank1-/- groups.
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Supplemental Table 1

Table 2: Gravimetric and echocardiographic data from naïve 12-16 wk old male and
-/+/+
female
mice.Table
*p<0.05
when we
cmPank1
cmPank1
.
Supplemental
1: Gravimetric
and compare
echocardiographic
data fromvs
naïve
12-16 wk old

male and female mice.

*p<0.05 when we compare cmPank1-/- vs cmPank1+/+.
Male

Female

Total mice (#)
Body weight (g)
HR (bpm)
SV (μL)
EDV (μL)
ESV (μL)
EF (%)
CO (mL/min)
LVIDd (mm)
LVIDs (mm)
LVPWd (mm)
LVPWs (mm)
LVAWd (mm)
LVAWs (mm)

cmPank1 +/+

cmPank1 -/-

9
20.8 ± 1.6
511 ± 52
23 ± 6
32 ± 8
9±3
72.0 ± 6.0
12.2 ± 2.3
3.4 ± 0.4
1.9 ± 0.4
0.9 ± 0.2
1.4 ± 0.2
1.1 ± 0.1
1.6 ± 0.2

12
21.5 ± 2.0
532 ± 39
24 ± 6
34 ± 9
10 ± 3
72.0 ± 5.0
13.0 ± 2.8
3.4 ± 0.3
1.9 ± 0.3
0.6 ± 0.2
1.4 ± 0.2
1.0 ± 0.1∗
1.5 ± 0.1

39

cmPank1 +/+ cmPank1 -/13
26.1 ± 1.9
523 ± 44
30 ± 8
40 ± 11
10 ± 3
74.5 ± 4.5
15.3 ± 4.0
3.7 ± 0.4
2.2 ± 0.5
0.9 ± 0.2
1.4 ± 0.2
1.1 ± 0.2
1.7 ± 0.2

13
26.7 ± 3.3
538 ± 48
27 ± 7
39 ± 11
12 ± 6
69.7 ± 6.2∗
14.3 ± 3.3
3.6 ± 0.4
2.2 ± 0.4
0.9 ± 0.2
1.3 ± 0.2
1.0 ± 0.1
1.6 ± 0.2

Next, the impact of Pank1 deletion on cardiac hypertrophy at baseline was assessed by
wheat germ agglutinin (WGA) staining. Consistent with no changes in cardiac fibrosis and
vascular density, our results suggest that Pank1 deletion had no significant impact on
cardiac hypertrophy (Figure 7A and 7B), which is consistent with no observable change in
heart weights as a result of Pank1 deletion (Figure 7C).
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Finally, the impact of Pank1 deletion on baseline transcriptional changes was assessed by
RNA-seq analysis of hearts. 17 protein coding genes were downregulated, and 24 protein
coding genes were upregulated as a result of Pank1 deletion (Figure 8A and 8B). Gene
Ontology (GO) enrichment analysis of differentially expressed protein coding genes
indicate that Pank1 deletion upregulates genes significantly involved in cellular oxidant
detoxification, erythrocyte development, skeletal muscle contraction, amongst other
processes (Figure 8C).

Collectively, these data suggest that cardiac Pank1 deletion

minimally affects basal cardiac function without affecting ventricular remodeling as
measured by fibrosis, vascular density, and hypertrophy in naïve hearts. Furthermore,
despite differences in transcriptional profiles associated with Pank1 deletion at baseline,
cardiac function and structure were minimally affected. The question, however, remained
as to whether cardiac Pank1 deletion, by limiting excessive acetylation, benefits the failing
heart.
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Figure 8: Impact of cardiomyocyte specific Pank1 deletion on cardiac
transcriptional profiles. To study the impact of Pank1 on cardiac transcriptional profile,
total RNA was isolated from naïve male (blue) and female (purple) cmPanK1+/+ and
cmPanK1-/- hearts. A) Volcano plot of differentially expressed genes in naïve hearts. B)
Heat map showing differentially regulated genes in cmPank1-/- naïve hearts compared to
cmPank1+/+. C) Gene Ontology (GO) enrichment analysis showing biological processes
associated with downregulated genes in cmPank1-/- compared to cmPank1+/+ hearts. D)
Gene Ontology (GO) enrichment analysis showing biological processes associated with
upregulated genes in cmPank1-/- compared to cmPank1+/+ hearts.
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cmPank1 deletion exacerbated cardiac dysfunction during pressure overload.
To determine whether cmPank1 deletion benefited cardiac function during pressure
overload, 12-16-week-old cmPank1-/- and cmPank1+/+ mice were subjected to transverse
aortic constriction (TAC) and cardiac function was assessed at 2-12 wk post-TAC by
echocardiography. Compared to cmPank1+/+, left ventricular end-diastolic (EDV) and
systolic (ESV) volumes were significantly increased in cmPank1-/- mice at 2 wk, and
continued to significantly dilate until 12 wk post-TAC (Figure 9A and 9B) in a sex
independent manner (Figure 10). Consistent with increased EDV and ESV, Pank1 deletion
resulted in significantly reduced ejection fraction (EF) at 2 wk and continued to decrease
until 8 wk post-TAC (Figure 9C) in a sex independent manner (Figure 10; Table 4 and 5).
Additionally, posterior wall thickness at diastole (LVPWd) and systole (LVPWDs) and left
ventricular anterior wall thickness at diastole (LVAWd) and systole (LVAWDs) were
significantly reduced as a result of Pank1 deletion (Table 3). We did not observe any
significant difference in body weight, heart rate (HR), stroke volume (SV), and cardiac
output (CO) at 2-12 wk post-TAC as a result of Pank1 deletion (Table 3). Collectively,
these data suggest that cardiac Pank1 deletion exacerbates cardiac dysfunction starting at
2 wk post-TAC. Given these observations, we next sought to investigate how PANK1
deletion contributes to exacerbated cardiac dysfunction during pressure overload.
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Figure 4: Pank1 deletion exacerbates ventricular dilation during pressure overload. Mice were subjected to

transverse9:aortic
constriction
(TAC) exacerbates
and echocardiography
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at 2, 4,during
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A) Left
Figure
Pank1
deletion
ventricular
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overload.
ventricular end diastolic volumes (EDV). B) Left ventricular end systolic volumes (ESV). C) Ejection fraction (EF).
An unpaired Student’s t test was used to determine significant differences between cmPank1+/+ and cmPank1-/Mice
were subjected to transverse aortic constriction (TAC) and echocardiography was
groups at each time point.

performed at 2, 4, 8, and 12 wk after TAC. A) Left ventricular end diastolic volumes (EDV).
B) Left ventricular end systolic volumes (ESV). C) Ejection fraction (EF). An unpaired
Student’s t test was used to determine significant differences between cmPank1+/+ and
cmPank1-/- groups at each time point.
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Supplemental Figure 3: Data from Figure 4 disaggregated by sex. A) Left ventricular end-diastolic volumes (EDV) in female mice. B) Left
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Left
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male mice. E) Left ventricular end systolic volumes (ESV) in male mice. F) Ejection fraction (EF) in male mice. An unpaired Student’s t test was
used to determine significant differences between cmPank1+/+ and cmPank1-/- groups at each time point.

volumes (EDV) in female mice. B) Left ventricular end-systolic volumes (ESV) in female
mice. C) Ejection fraction (EF) in female mice. D) Left ventricular end diastolic volumes
(EDV) in male mice. E) Left ventricular end systolic volumes (ESV) in male mice. F)
Ejection fraction (EF) in male mice. An unpaired Student’s t test was used to determine
significant differences between cmPank1+/+ and cmPank1-/- groups at each time point.
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Table 3: Echocardiography data of mice subjected to TAC. An unpaired Student’s t
test was used to determine significant differences between cmPank1+/+ and cmPank1-/groups. *p<0.05 when we compare cmPank1-/- vs cmPank1+/+ at each time point and
number of animals at each time point is the same indicated in Figure 9.
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Table 4: Data from Table 3 disaggregated by female sex. Echocardiography data of
female mice subjected to TAC. An unpaired Student’s t test was used to determine
significant differences between cmPank1+/+ and cmPank1-/- groups. *p<0.05 when we
compare cmPank1-/- vs cmPank1+/+ at each time point and number of animals at each time
point is the same indicated in Figure 10.
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Table 5: Data from Table 3 disaggregated by male sex. Echocardiography data of male
mice subjected to TAC. An unpaired Student’s t test was used to determine significant
differences between cmPank1+/+ and cmPank1-/- groups. *p<0.05 when we compare
cmPank1-/- vs cmPank1+/+ at each time point and number of animals at each time point is
the same indicated in Figure 10.
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cmPank1 deletion impacted transcriptional landscape related to fibrotic and
metabolic processes during pressure overload.
To investigate how Pank1 deletion contributes to exacerbated cardiac dysfunction during
pressure overload, total RNA was isolated from cmPank1-/- and cmPank1+/+ male and
female hearts at 12 wk post-TAC and subjected to unbiased bulk RNA-seq analysis. 50
protein coding genes were downregulated, and 75 protein coding genes were upregulated
as a result of Pank1 deletion (Figure 11A-C). Gene Ontology (GO) enrichment analysis of
differentially expressed genes indicate that Pank1 deletion downregulates genes
significantly involved in cellular oxidant detoxification, muscle contraction, circadian
rhythm, fatty acid metabolic process, and regulation of slow-twitch skeletal muscle fiber
contraction amongst other processes (Figure 11D) in cmPank1-/- hearts. Genes involved
in cell cycle, cycle division, response to mechanical stimulus, positive regulation of
fibroblast proliferation, and SMAD protein signal transduction amongst other processes
were upregulated (Figure 11D). Taken together, these data suggest a role of Pank1 in
regulating fibrotic and metabolic processes during pressure overload. We then sought to
determine how PANK1 regulates remodeling and metabolic processes during TAC.
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cmPank1 deletion exacerbated fibrosis without affecting vascular density,
hypertrophy, or apoptosis during pressure overload.
To determine whether cmPank1 deletion contributes to adverse ventricular remodeling, we
assessed the impact of partial CoA depletion on several indices of ventricular remodeling
like hypertrophy, fibrosis, vascular density, and apoptosis by wheat germ agglutinin
(WGA), trichrome, isolectin B4, and TUNEL staining after final echocardiography at 12
wkpost-TAC. Cardiac hypertrophy was not significantly changed as a result of Pank1
deletion (Figure 11A and B). Consistent with WGA staining, we did not observe significant
differences in normalized heart weights (HW) as a result of Pank1 deletion (Figure 11C).

Figure 11: Cardiomyocyte Pank1 deletion impacts transcriptional profile of fibrotic
and metabolic processes at 12 wk post pressure overload. Total RNA was isolated
from hearts 12 wk post TAC and RNA-Seq was performed. A) Volcano plot of differentially
expressed genes. B) Heat map showing upregulated genes in male (blue) and female
(purple) hearts. C) Heat map showing downregulated genes in male (blue) and female
(purple) hearts. D) Gene Ontology (GO) enrichment analysis showing biological processes
associated with downregulated and upregulated genes in cmPank1-/- compared to
cmPank1+/+ hearts.
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Next, to determine whether cmPank1 deletion contributes to adverse ventricular
remodeling, we assessed the impact of partial CoA depletion on several indices of
ventricular remodeling like hypertrophy, fibrosis, vascular density, and apoptosis by wheat
germ agglutinin (WGA), trichrome, isolectin B4, and TUNEL staining after final
echocardiography at 12 wk post-TAC. Cardiac hypertrophy was not significantly changed
as a result of Pank1 deletion (Figure 12A and 12B). Consistent with WGA staining, we did
not observe significant differences in normalized heart weights (HW) as a result of Pank1
deletion (Figure 12C).
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Figure 12: Cardiomyocyte specific Pank1 deletion does not affect cardiomyocyte
size 12 wk post TAC. We assessed cardiomyocyte size by wheat germ agglutinin (WGA)
and measuring heart weights. A) WGA stained (red) hearts. B) Quantification of WGA
stained hearts. C) Heart weight/tibia length ratio. An unpaired Student’s t test was used to
determine significant differences between cmPank1+/+ and cmPank1-/- groups.
.
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Next, the impact of Pank1 deletion on cardiac fibrosis was assessed at 12 wk post-TAC.
Interestingly, cardiac fibrosis was significantly increased as a result of Pank1 deletion
(Figure 13A and B). This is further supported by our RNAseq data that showed
upregulation of genes involved in fibrotic and ECM remodeling, including Acta2, Inhhb,
Gdf15, Gdf6, Fbn2, Tnc, and Timp1 amongst others (Figure 13C-F).
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Furthermore, our results indicate no significant changes in vascular density as a result of
Pank1 deletion (Figure 14A and 14B). Finally, we assessed the impact of Pank1 deletion
on cardiac apoptosis. Our results indicate no significant changes in apoptosis as a result
of Pank1 deletion (Figure 14C and 14D). Collectively, these data suggest that cardiac
PANK1 deletion exacerbates cardiac fibrosis without affecting vascular density,
hypertrophy, and apoptosis at 12 wk post pressure overload.
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cmPank1 deletion altered metabolites involved in substrate utilization early during
pressure overload.
To determine how Pank1 deletion alters cardiac metabolism in naïve animals and during
pressure overload, cmPank1-/- and cmPank1+/+ male and female mice were subjected to
TAC (Table 6) and cardiac metabolism was assessed by LC-MS at 2 wk post-TAC.
Principal component analysis (PCA) of global metabolic profiles reveals clear separations
as a result and Pank1 deletion (Figure 15A). Although both female and male mice were
included in this study, clustering pattern was not widely affected as a result of sex (Figure
15A). In naïve mice, 36 metabolites were significantly changed as a result of Pank1
deletion. Pathway enrichment analysis of significantly changed metabolites suggests that
Pank1 deletion significantly impacts metabolites involved in the pantothenate and CoA
biosynthetic pathway, ketone body metabolism, pentose phosphate pathway, amino sugar
metabolism, and fatty acid biosynthesis among other pathways (Figure 15B). Interestingly,
during TAC, 71 metabolites were significantly changed as a result of Pank1 deletion.
Pathway analysis of significantly changed metabolites suggests that during TAC, Pank1
deletion significantly impacts metabolites involved in butyrate metabolism, pantothenate
and CoA biosynthesis, ketone body metabolism, mitochondria beta-oxidation of short,
medium, long, and very long chain saturated fatty acids, aspartate metabolism and
arginine and proline metabolism among other metabolic processes (Figure 15D). Because
ketone body consumption increases during heart failure, we further examined metabolites
involved in ketone oxidation as a result of Pank1 deletion.

58

Table 6: Gravimetric and echocardiographic data from a separate cohort of mice
subjected to TAC for 2 wk for metabolomics analysis. *p<0.05 when we compare cmPank1/-

(n=6) vs cmPank1+/+ (n=6).
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Figure 15: Cardiomyocyte Pank1 deletion alters metabolites involved in substrate
utilization after 2 wk of pressure overload. A) Principal component analysis (PCA) plot.
B) Metabolite set enrichment analysis in naïve animals. C) Variable of importance (VIP)
plot of animals subjected to TAC. D) Metabolite set enrichment analysis in animals
subjected to TAC.
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Interestingly, levels of 3-hydroxybutyrate were significantly increased in naïve mice as a
result of Pank1 deletion (Figure 16A). Similarly, during TAC, we observed an elevated (but
not significant p=0.0649) 3-hydroxybutyrate level (Figure 16B).
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Furthermore, Pank1 deletion resulted in significant reduction in precursors required for
succinyl-CoA synthesis such as propionyl-CoA, acetyl-CoA, and methylmalonyl-carnitine
during TAC (Figure 17). Because succinyl-CoA is required for the transfer of CoA during
ketone body oxidation (during the conversion of acetoacetate to acetoacetate-CoA by
SCOT1), our data suggest that Pank1 deletion may limit succinyl-CoA levels and that may
impinge on ketone body oxidation in the heart—hence elevated levels of 3hydroxybutyrate level.
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Figure 17: Succinyl-CoA precursors are decreased 2 wk post-TAC. Unbiased
metabolomics analysis of metabolites involved in the citric acid cycle. An unpaired
Student’s t test was used to determine significant differences between cmPank1+/+ and
cmPank1-/- hearts.
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We next examined the impact of Pank1 deletion on acyl-carnitines. Interestingly, betahydroxyisovaleroyl-carnitine, 2-methylbutyryl-carnitine, and lignoceroyl-carnitine were
significantly

elevated

while

methylsuccinoyl-carnitine,

succinyl-carnitine,

and

methylmalonyl-carnitine were significantly downregulated in naïve hearts (Figure 18).
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66

However, during TAC, Pank1 deletion resulted in significant accumulation of acylcarnitines, including, isobutyryl-carnitine, butenoyl-carnitine, isovaleryl-carnitine, tiglycarnitine, 2-methylbutyryl-carnitine, arachidoyl-carnitine, eicosenoyl-carnitine, behenoylcarnitine, erucoyl-carnitine, lignoceroyl-carnitine, and nervonoyl-carnitine. Interestingly,
consistent with our naïve data, succinyl-carnitine and 2-methylmalonyl-carnitine were
significantly downregulated (Figure 19).
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Finally, during TAC, Pank1 deletion led to significant elevation of metabolites involved in
tissue remodeling including 4-hydroxycinnamate sulfate, 4-methylcatechol sulfate, proline,
ornithine, arginosuccinate, and 2'-AMP were significantly elevated during TAC as a result
of Pank1 deletion among other metabolites (Table 7). Collectively, these data suggest that
Pank1 deletion results to significant changes to metabolites associated with energy
metabolism, substrate utilization and tissue remodeling early during pressure overload.
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Table 7: Changes in metabolites in cmPank1-/- hearts subjected to TAC for 2 wk
compared to cmPank1+/+ hearts.

70

Specific Aim 3
Mitochondria isolated from failing hearts have increased acetylation and reduced
respirasome.
To assess changes in mitochondrial acetylation and respirasome during HF, mitochondria
isolated from failing and non-failing human hearts were assessed by immunoblotting.
Compared to non-failing heart (NF), mitochondrial acetylation was significantly increased
in failing hearts (HF) (Figure 20A and 20B). This finding is consistent with a previously
published study101. Several studies suggest an alteration in mitochondria electron
transport chain (ETC) during heart failure159. To assess the changes in mitochondria
respirasome during heart failure, mitochondria isolated from failing and non-failing human
hearts were assessed by BN-PAGE analysis. Consistent with increased mitochondria
acetylation observed in the failing hearts, mitochondria respirasome were decreased in
HF mitochondria compared to non-failing heart mitochondria (Figure 20C and 20D).
Collectively, this data suggests that mitochondria isolated from the failing hearts have
increased acetylation and reduced respirasomes. Given these observations, we next
sought to determine whether acetylation levels directly affect mitochondria bioenergetics
and respirasomes.

71

Figure 20: Mitochondria isolated from failing hearts have increased acetylation and
reduced respirasomes. A) Mitochondrial acetylation in non-failing (NF) and heart failure (HF)
hearts. B) Quantification of mitochondrial acetylation in non-failing (NF) and heart failure (HF)
hearts. C) BN-PAGE analysis of mitochondrial respirasome assembly isolated from non-failing
(NF) and heart failure (HF) mitochondria. D) Quantification of BN-PAGE analysis of
mitochondrial respirasome assembly isolated from non-failing (NF) and heart failure (HF)
mitochondria. An unpaired Student’s t test was used to determine significant differences
between NF and HF groups.
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Mitochondria hyperacetylation suppresses state 3 supported respiration in the
presence of complex II and fatty acid oxidation substrates, without affecting state 3
respiration in the presence of complex I substrates.
To determine whether changing mitochondria acetylation directly regulates mitochondria
bioenergetics, we induced mitochondria hyperacetylation in isolated mitochondria by
acetic anhydride treatment as previously described160. Increasing concentration of acetic
anhydride induced a concentration dependent increase in mitochondria acetylation
(Figure 21A and 21B). Next, to determine whether mitochondrial hyperacetylation affect
mitochondria respiratory functions, we measured state 3 respiration in the presence of CI (pyruvate/malate/ADP), C-II (succinate/rotenone/ADP), and fatty acid oxidation
(octanoylcarnithine/malate/ADP) substrates in mitochondria treated with 50 µM of acetic
anhydride¾to induce hyperacetylation. Compared to vehicle control, we did not observe
significant difference in state 3 respiration in the presence of C-I substrates in
mitochondria treated with 50 µM of acetic anhydride (Figure 21C). Interestingly, compared
to vehicle control, state 3 respiration was suppressed in the presence of complex II and
fatty acid oxidation substrates in mitochondria treated with 50 µM of acetic anhydride
(Figure 21D-21E). Suggesting that mitochondria hyperacetylation may directly impact CII respiration and fatty acid oxidation, but not C-I respiration.

73

Figure 21: Mitochondrial hyperacetylation suppresses state 3 respiration in the
presence of complex II and fatty acid oxidation substrates. Mitochondria
hyperacetylation was induced by treating isolated mitochondria with increasing
concentrations of Ac2O and mitochondria function was assessed by extracellular flux
analysis. A) Concentration dependent induction of mitochondrial hyperacetylation by Ac2O
treatment. B) Quantification of mitochondrial acetylation by Ac2O treatment. C) Assessing
state 3 respiration using pyruvate, malate and ADP (PMA) as complex I substrates. D)
Assessing state 3 respiration using succinate, rotenone and ADP (SRA) as complex II
substrates. E) Assessing medium chain fatty acid oxidation supported state 3 respiration
using octanoylcarnitine, malate and ADP (OMA) as substrate. An unpaired Student’s t test
was used to determine significant differences between vehicle and Ac2O treated groups.
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Mitochondrial acetylation alone does not affect supercomplexes.
To determine whether changing mitochondria acetylation directly regulates mitochondria
bioenergetics, mitochondria from cmPank1-/-—which have reduced mitochondrial
acetylation—were isolated and analyzed BN-PAGE. We did not observe any significant
changes to mitochondria supercomplexes when we limit mitochondria acetylation (Figure
22A and 22B). Furthermore, to assess the impact of mitochondria hyperacetylation on
respirasome, isolated mitochondria were treated with 50 µM of acetic anhydride to induce
mitochondria hyperacetylation and respirasome was assessed by BN-PAGE. Compared
to vehicle treated hearts, mitochondrial hyperacetylation alone does not appear to impair
mitochondrial respirasome (Figure 22C).
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CHAPTER V
DISCUSSION
Recent studies have associated elevated acetyl-CoA levels with heart failure in humans19.
This association, in part, may involve enhanced acetylation, which is thought to promote
pathology. Several studies suggest that elevated acetyl-CoA may promote enzyme
independent acetylation of cardiac and mitochondrial proteins161,

162

, contributing to

mitochondria dysfunction67, 163-165. Here, we sought to limit CoA levels to curb excessive
acetylation during heart failure. We hypothesized that deleting Pank1 will limit available
CoA pools, which would limit acetylation and thereby attenuate ventricular remodeling
during pressure overload. Our results show that although constitutive, cardiomyocyte
restricted Pank1 deletion decreased acetyl-CoA levels during TAC, this intervention
exacerbated ventricular remodeling during pressure overload. Lastly, our results suggest
that metabolic alterations, rather than structural alterations associated with Pank1
deletion, may underlie the exacerbated cardiac phenotype during pressure overload.

Acetylation of cardiac proteins has been associated with a decline in mitochondria
function67,

163-166

; however, recent studies have challenged the deleterious nature of

mitochondrial hyperacetylation167. Although we hypothesized that targeting enzyme
independent acetylation would be beneficial, our data suggest that metabolic changes,
rather than CoA-driven enzyme independent acetylation, may be more important in the
context of heart failure. It is, therefore, possible that hyperacetylation may not be
deleterious because our attempt to limit acetylation did not improve cardiac function. More
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importantly, the intervention of deleting Pank1 did not impact only acetylation; it likely
impacted other metabolic events following TAC.

Additionally, although studies have linked other enzyme dependent mechanisms, such as
sirtuins and NAD+ to protein hyperacetylation101, 143, others suggest that mitochondrial
acetylation is largely enzyme independent and depends on the availability of substrates
such as acetyl-CoA161, 162—hence our rationale to limit acetyl-CoA. Yet, we did not observe
significant transcriptional changes in SIRT3 or NAD+, suggesting that our method of
limiting mitochondrial acetylation may be independent of SIRT3 and NAD+ pathway.

To explore more proximal metabolic relationships to explain why Pank1 deletion may have
exacerbated heart failure, we focused on potential impacts at the level of intermediary
metabolism. One prominent observation from our studies is the dysregulation of
metabolites in the ketone body pathway because of Pank1 deletion. The failing heart may
at least partially rely on ketones for energy168,

169

. Our metabolomics data suggest

suppressed oxidation of ketones as indicated by elevated 3-hydroxybutyrate at baseline
and during TAC, and significant reduction in precursors required for succinyl-CoA
synthesis such as propionyl-CoA, acetyl-CoA, succinyl-carnitine, and methylmalonylcarnitine. Although our metabolomics data did not detect levels of succinyl-CoA during
TAC, we can speculate from our data that succinyl-CoA may be limiting. Because succinylCoA is required for the transfer of CoA during ketone body oxidation (during the conversion
of acetoacetate to acetoacetate-CoA by SCOT1), an intervention potentially limiting
succinyl-CoA levels may be suppressing a shift to ketones as a source of energy during
heart failure. In other words, it is possible that limiting CoA pools impinged on the ability
of cardiomyocyte to utilize ketone bodies for fuel, due to shortfall of metabolites required
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to oxidize ketones. Thus, given that ketone body utilization is inadequate in the failing
heart, it is possible that Pank1 deletion further exacerbated this energetic crisis.

The impact of Pank1 deletion on acyl-carnitine levels was also assessed. Interestingly,
Pank1 deletion resulted in significant accumulation of short, medium, and long chain acylcarnitine in naïve and TAC animals. Succinyl-carnitine and 2-methylmalonyl-carnitine
were significantly downregulated in naïve and TAC animals, strongly suggesting a
potential role of CoA in regulating succinyl-carnitine and 2-methylmalonyl-carnitine levels.
Additionally, we did not observe any changes in mitochondria structure during TAC as a
result of Pank1 deletion (Figure 23). Suggesting that suppressed substrate utilization,
rather than mitochondria dysfunction may be promoting the accumulation of acylcarnitines as a result of Pank1 deletion. Our data is consistent with previously published
work that suggests that liver CoA depletion resulted in reduced fatty acid oxidation as
evident by the accumulation of acyl-carnitines126. In summary, our data indicates a role of
cardiac CoA in regulation fatty acid oxidation.
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Figure 23: Mitochondria size is not affected as a result of Pank1 deletion. A) TEM
images of mitochondria. B) Quantification of mitochondria area. An unpaired Student’s t
test was used to determine significant differences between cmPank1+/+ and cmPank1-/hearts.
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Furthermore, studies have shown that acyl-CoA pools are decreased, and that preserving
acyl-CoA availability attenuates pathological and metabolic remodeling170. Unfortunately,
our platform did not provide broad coverage of significantly changed acyl-carnitine and
acyl-CoA metabolites in WT mice. Nevertheless, our intervention to limit acetyl-CoA in
cardiomyocytes by Pank1 deletion minimally impacted the overall cardiac acyl-CoA pool
(of those for which we had coverage) at baseline and following TAC—with the exception
of acetyl-CoA.

The group differences in ventricular dimensions prompted us to query a potential impact
at the level of fibrosis. Indeed, our pathology data indicated that loss of PANK1 resulted
in increased fibrosis during pressure overload. This observation was further corroborated
by our unbiased RNA-seq data, which showed upregulation of a-smooth muscle actin
(Acta2), a marker of myofibroblast activation, indicating that Pank1 deletion promotes a
myofibroblast phenotype in the heart during pressure overload. Furthermore, Pank1
deletion also resulted in increased mRNA expression of TGF-b family of proteins, including
inhibin beta B (Inhhb), growth differentiation factor 15 (Gdf15), growth differentiation factor
6 (Gdf6), and bone morphogenic peptide 10 (Bmp10)—some of which have been shown
to be involved in fibroblast proliferation, myofibroblast differentiation, myocardial fibrosis,
and extracellular matrix protein deposition171-173. Interestingly, these data are further
supported by GO analyses, which suggest that Pank1 deletion upregulates genes involved
in positive regulation of fibroblast proliferation. Additionally, Pank1 deletion also
upregulated genes of extracellular matrix (ECM) remodeling proteins, including, fibrilin-2
(Fbn2), arylsulfatase I (Arsi), tenascin C (Tnc), elastin (Eln), neuron derived neurotrophic
factor

(Ndnf),

tissue

inhibitor

of

metalloproteinases

1

(Timp1),

and

ADAM

metallopeptidase with thrombospondin type 1 motif 4 (Adamts4). Upregulation of these
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enzymes has been implicated in a variety of cardiac fibrotic and inflammatory responses
174-177

. These data were further supported by our metabolomics data indicating differential

abundances in metabolites involved in collagen metabolism, including proline and
arginosuccinate—a precursor for arginine. Collectively, these data suggest a role of CoA
metabolism in regulating fibrosis and collagen turnover in the heart. However, it is possible
that other changes occurred upstream of this enhanced fibrotic response to contribute to
this observed fibrotic phenotype. Nevertheless, whether a more direct relationship exists
between intracellular CoA metabolism and the fibrotic response in the heart is intriguing
and will be pursued in future studies.

Coincident with changes in acetylation levels during heart failure, the stoichiometry of the
mitochondrial respirasome is changed99; these changes are associated with a decline in
mitochondrial energetics99,

178

. Nevertheless, the question of whether changes in

mitochondrial acetylation levels directly affect respirasome and mitochondrial function was
one of the questions we asked. Our results suggest that limiting mitochondria acetylation
does not affect mitochondrial dynamics, function, and respirasomes. Additionally,
although we did not observe changes to mitochondrial respirasomes when we induced
mitochondrial hyperacetylation, our data suggest that hyperacetylation may suppress
complex II and fatty acid supported respiration. This is consistent with previously published
studies101, 179. Horton et al.15 recently showed that succinate dehydrogenase (SDHA)—a
key in both the TCA cycle and respiratory C-II—is acetylated at multiple sites with heart
failure in human and mice. Furthermore, Horton et al.15 also showed that directly
increasing acetylation of SDHA—using an acetyl-mimetic point mutation—was sufficient
to suppress C-II respiratory functions. Consistent with suppressed state 3 respiration with
hyperacetylation in the presence of C-II substrates, our data also suggest that state 3
respiration in the presence of fatty acid is also suppressed. However, we did not observe
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any significant difference in state 3 respiration in the presence of C-I substrates.
Conversely, limiting mitochondria acetylation does not impact overall mitochondria
energetics and dynamics. Collectively, our data suggest that acetylation of mitochondrial
proteins may play a minimal role in the assembly of respirasomes. Also, our results
suggest that hyperacetylation of mitochondria proteins alone may be sufficient to impact
mitochondria respiratory functions.

In terms of rigor and reproducibility, this study was planned, blinded, and appropriately
controlled. Furthermore, this study used both male and female mice, both of which
responded similarly to Pank1 deletion in response to pressure overload. We have
frequently used the TAC model of heart failure and are able to create consistent stenoses
in adult mice. Our approach of using cell type-specific ablation of Pank1 has several issues
worthy of consideration. In terms of advantages, our approach avoids the broad, systemic
effects of administering a PANK inhibitor. Such an inhibitor would impact other organs,
including the liver, and, if sufficiently potent, would completely eliminate CoA levels; this,
of course, would be incompatible with life. Deleting only one of the PANK isoforms partially
limited CoA pools allowing us to test our hypothesis. Although there are two other PANK
isoforms, we did not observe compensation at the level of mRNA of Pank2 or Pank3.
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CHAPTER VI
SUMMARY AND FUTURE DIRECTION
Heart failure is characterized by hyperacetylation of mitochondrial proteins101. Because
studies have shown that increased acetylation levels in tissues such as the heart, liver,
and skeletal muscle correlate with a decline in oxidative phosphorylation67, 163-165, we
tested the question of whether limiting mitochondrial acetylation will be beneficial during
heart failure. Because both N-a-acetylation and N-e-acetylation depends on the availability
of acetyl-CoA, and synthesis of acetyl-CoA is partly dependent on the availability of an
acyl carrier—Coenzyme A (CoA)39, we sought to restrict cardiac mitochondria acetylation
by limiting CoA levels (via Pank1 deletion). Our results show that CoA depletion limited
overall mitochondrial acetylation compared to controls. Furthermore, results show that
although limiting mitochondria acetylation minimally affects cardiac function at baseline,
cardiac dysfunction was exacerbated during pressure overload compared to the control.

Because limiting mitochondrial acetylation exacerbated cardiac function, we next
assessed the impact of Pank1 deletion on other endpoints of ventricular remodeling. At
baseline, limiting mitochondrial acetylation did not affect fibrosis, hypertrophy, and
vascular density. However, our data suggest that limiting mitochondria acetylation
exacerbates cardiac fibrosis without affecting myocyte hypertrophy and vascular density
during TAC. To identify possible mechanisms contributing to increased fibrosis and
exacerbated cardiac function associated with limiting mitochondrial acetylation during
TAC, we performed RNA-seq analysis during TAC. Interestingly, limiting mitochondria
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acetylation via Pank1 deletion resulted in the downregulation of genes involved in various
metabolic and fibrotic processes, including metabolites involved in ketone body, fatty acid,
and tissue remodeling.

We also investigated whether changing mitochondrial acetylation alone¾i.e., increasing
or decreasing acetylation¾was sufficient to induce mitochondrial dysfunction. Our results
suggest that mitochondrial hyperacetylation suppresses state 3 respiration in the presence
of C-II substrates and fatty acids compared to vehicle controls. Collectively, our results
suggest that hyperacetylation of mitochondria proteins alone may be sufficient to impact
mitochondria respiratory functions.

Coincident with elevated mitochondria acetylation levels during heart failure, the
stoichiometry of the mitochondrial respirasome is changed99; these changes are
associated with a decline in mitochondrial energetics99, 178. We then sought to determine
whether changing mitochondria acetylation alone was sufficient to impact respirasomes.
Although our results show that mitochondrial respirasome is destabilized in human failing
hearts, inducing hyperacetylations by acetic anhydride treatment did not sufficiently impact
respirasomes. Similarly, limiting mitochondrial acetylation did not impact respirasomes.
Suggesting that changing acetylation alone does not influence respirasome assembly.

To briefly summarize, we decreased acetylation by limiting cardiac CoA levels via
cardiomyocyte-restricted deletion of Pank1, which is the rate-limiting enzyme in CoA
biosynthesis. Contrary to our predictions, Pank1 deletion exacerbated ventricular
remodeling. This created a serendipitous opportunity for us to explore why this may have
been the case. The results of our exploration suggest that CoA availability may be more
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beneficial in terms of sustaining cardiac ketone body metabolism and substrate utilization
(Figure 24A and B). Also, we showed that acetylation alone does not impact mitochondrial
respirasomes.

86

Figure 24: Summary of Findings. Metabolic dysregulation occurring in heart failure
promotes accumulation of acetyl-CoA. Acetyl-CoA accumulation can drive enzyme
independent acetylation of mitochondrial function and is associated with a decline in
cardiac function (Figure 24A). We hypothesized that limiting acetyl-CoA can reduce
mitochondrial acetylation and be pro-adaptive during heart failure. We generated a
cardiomyocyte-specific Pank1 deficient mice (cmPank1-/-) as a model of reduced
acetyl-CoA. We showed that even though cmPank1-/- have reduced Acetyl-CoA and
reduced mitochondrial acetylation, cardiac dysfunction was exacerbated as a result of
Pank1 deletion (Figure 24B).
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In terms of potentially translating the present insights, our data argue against a strategy
of limiting CoA to limit acetylation. Future studies will investigate the impact of CoA levels
on ketone body and fatty acid oxidation during heart failure. We will utilize the ex vivo
working heart model to investigate the direct impact of increasing or decreasing CoA levels
on ketone body and fatty acid oxidation. To deplete cardiac CoA levels, we will utilize or
cardiomyocyte specific Pank1 knockout model (cmPank1-/-). Furthermore, we will activate
PANK (to increase CoA levels) using a feeding diet containing 75 ppm of pantazine (PZ3022)—this concentration has been shown to sufficiently activate cardiac PANK and CoA
levels146. Similarly, we will assess the impact of increasing CoA on cardiac function and
remodeling during pressure overload. Given the important role of CoA in regulating
intermediary metabolism and substrate utilization in the failing heart as indicated by our
data, this study will answer the question of whether increasing CoA is sufficient to improve
cardiac function by improving utilization of fatty acid and ketones during pressure
overload.

Also, because another pathological feature associated with Pank1 deletion during heart
failure was increased fibrosis, future studies will investigate the link between CoA and
fibrosis in the context of heart failure. During heart failure, activated fibroblasts are
primarily responsible for initiating fibrotic responses. Because we observed significantly
increased fibrosis as a result of cardiomyocyte specific Pank1 knockout model (cmPank1/-

), we speculate that a paracrine mechanism between cardiomyocyte and fibroblast may

be regulating this increased fibrosis phenotype. To test this, we will utilize a co-culture
technique to test the question of whether secretory factors produced from cardiomyocyte
lacking Pank1 is sufficient to activate fibroblast in vitro using co-culture techniques. This
future experiment will assess mechanisms by which cardiomyocyte specific Pank1
deletion contributes to cardiac fibrosis.
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Finally, although our data suggest that changing acetylation levels minimally impacts
mitochondria supercomplexes, several questions remain unanswered. First, although we
successfully depleted acetyl-CoA (which is the driving force for enzyme dependent
mitochondrial acetylation), we did not assess mitochondria acetylation during pressure
overload. Assessing acetylation levels in cmPank1-/- may provide additional insight on the
extent to which Pank1 deletion may be impacting mitochondrial acetylation compared to
its role in regulating cardiac metabolism.
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